We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cabot's Earnings and Revenues Lag Estimates in Q1, EPS Up Y/Y
Read MoreHide Full Article
Cabot Corporation (CBT - Free Report) logged net income of $93 million or $1.67 per share for the first quarter of fiscal 2025 (ended Dec. 31, 2024), a rise from the prior-year quarter’s profits of $50 million or 88 cents per share.
Barring one-time items, adjusted earnings per share (EPS) were $1.76 in the reported quarter, up from $1.56 in the year-ago quarter. The figure, however, missed the Zacks Consensus Estimate of $1.80.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Sales of $955 million missed the Zacks Consensus Estimate of $993 million. The metric also dropped roughly 0.3% on a year-over-year basis.
Cabot Corporation Price, Consensus and EPS Surprise
Reinforcement Materials’ sales decreased 4.7% year over year to $611 million in the reported quarter. It missed the Zacks Consensus Estimate of $664.2 million. Reinforcement Materials' first-quarter fiscal 2025 EBIT increased by $1 million from the first quarter of fiscal 2024. This was largely driven by volume growth and favorable pricing and product mix from calendar year 2024’s customer agreements.
Sales in the Performance Chemicals unit went up by 9.1% to $311 million in the reported quarter compared to the year-ago quarter’s $285 million. It beat the Zacks Consensus Estimate of $296.1 million. EBIT in Performance Chemicals grew $11 million year over year, owing to an 8% rise in volumes because of underlying demand drivers in key end markets.
CBT’s Financial Position
The company had a cash balance of $183 million at the end of the fiscal first quarter. Cash flows from operating activities were $124 million. Capital expenditures totaled $77 million. During the quarter, cash was also used for dividend payments of $24 million and share repurchases of $42 million.
CBT’s Outlook
Cabot expects adjusted earnings per share for fiscal 2025 to range between $7.40 and $7.80, factoring in business segment results and customer agreements. The outlook considers foreign exchange rates and interest rate projections but excludes potential tariff impacts. Strong operating cash flow is anticipated, supporting strategic growth investments and shareholder returns. The company remains confident in its execution capabilities and ability to navigate market conditions. Cabot continues to advance its "Creating for Tomorrow" strategy, aiming for long-term value creation.
CBT Stock’s Price Performance
CBT stock has gained 19.3% in the past year compared with the 5% growth of the industry.
NGVT is slated to report fourth-quarter results on Feb. 18. The Zacks Consensus Estimate for Ingevity’s fourth-quarter earnings is pegged at 12 cents per share. NGVT beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with the average surprise being 95.4%. Its shares have gained 2.1% in the past year.
ICL is scheduled to report fourth-quarter results on Feb. 26. The Zacks Consensus Estimate for ICL Group’s fourth-quarter earnings is pegged at 6 cents per share. ICL beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 18.1%. Its shares have soared 30% in the past year.
FSM is expected to report fourth-quarter results on March 5. The Zacks Consensus Estimate for Fortuna’s fourth-quarter earnings is pegged at 16 cents per share. FSM surpassed the Zacks Consensus Estimate in two of the trailing four quarters while missing it in the rest, with an average surprise of 53.6%. The stock has gained 67.7% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cabot's Earnings and Revenues Lag Estimates in Q1, EPS Up Y/Y
Cabot Corporation (CBT - Free Report) logged net income of $93 million or $1.67 per share for the first quarter of fiscal 2025 (ended Dec. 31, 2024), a rise from the prior-year quarter’s profits of $50 million or 88 cents per share.
Barring one-time items, adjusted earnings per share (EPS) were $1.76 in the reported quarter, up from $1.56 in the year-ago quarter. The figure, however, missed the Zacks Consensus Estimate of $1.80.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Sales of $955 million missed the Zacks Consensus Estimate of $993 million. The metric also dropped roughly 0.3% on a year-over-year basis.
Cabot Corporation Price, Consensus and EPS Surprise
Cabot Corporation price-consensus-eps-surprise-chart | Cabot Corporation Quote
CBT’s Segment Highlights
Reinforcement Materials’ sales decreased 4.7% year over year to $611 million in the reported quarter. It missed the Zacks Consensus Estimate of $664.2 million. Reinforcement Materials' first-quarter fiscal 2025 EBIT increased by $1 million from the first quarter of fiscal 2024. This was largely driven by volume growth and favorable pricing and product mix from calendar year 2024’s customer agreements.
Sales in the Performance Chemicals unit went up by 9.1% to $311 million in the reported quarter compared to the year-ago quarter’s $285 million. It beat the Zacks Consensus Estimate of $296.1 million. EBIT in Performance Chemicals grew $11 million year over year, owing to an 8% rise in volumes because of underlying demand drivers in key end markets.
CBT’s Financial Position
The company had a cash balance of $183 million at the end of the fiscal first quarter. Cash flows from operating activities were $124 million. Capital expenditures totaled $77 million. During the quarter, cash was also used for dividend payments of $24 million and share repurchases of $42 million.
CBT’s Outlook
Cabot expects adjusted earnings per share for fiscal 2025 to range between $7.40 and $7.80, factoring in business segment results and customer agreements. The outlook considers foreign exchange rates and interest rate projections but excludes potential tariff impacts. Strong operating cash flow is anticipated, supporting strategic growth investments and shareholder returns. The company remains confident in its execution capabilities and ability to navigate market conditions. Cabot continues to advance its "Creating for Tomorrow" strategy, aiming for long-term value creation.
CBT Stock’s Price Performance
CBT stock has gained 19.3% in the past year compared with the 5% growth of the industry.
Image Source: Zacks Investment Research
CBT's Zacks Rank & Key Picks
CBT currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Ingevity Corporation (NGVT - Free Report) , ICL Group Ltd. (ICL - Free Report) and Fortuna Mining Corp. (FSM - Free Report) . While NGVT sports a Zacks Rank #1 (Strong Buy), ICL and FSM each carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
NGVT is slated to report fourth-quarter results on Feb. 18. The Zacks Consensus Estimate for Ingevity’s fourth-quarter earnings is pegged at 12 cents per share. NGVT beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with the average surprise being 95.4%. Its shares have gained 2.1% in the past year.
ICL is scheduled to report fourth-quarter results on Feb. 26. The Zacks Consensus Estimate for ICL Group’s fourth-quarter earnings is pegged at 6 cents per share. ICL beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 18.1%. Its shares have soared 30% in the past year.
FSM is expected to report fourth-quarter results on March 5. The Zacks Consensus Estimate for Fortuna’s fourth-quarter earnings is pegged at 16 cents per share. FSM surpassed the Zacks Consensus Estimate in two of the trailing four quarters while missing it in the rest, with an average surprise of 53.6%. The stock has gained 67.7% in the past year.